by TractManager | Nov 11, 2019 | Emerging Technology Report
Ruzurgi (amifampridine, base form) is an oral drug intended for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in children aged 6 to < 17 years. Ruzurgi is a voltage-gated potassium channel inhibitor that prolongs the depolarization of the pre-synaptic cell...
by TractManager | Nov 6, 2019 | Emerging Technology Report
Firdapse (amifampridine phosphate) is an oral voltage-gated potassium channel inhibitor for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. Firdapse increases the release of acetylcholine from nerve cells, prolonging the depolarization...
by TractManager | Nov 6, 2019 | Health Technology Assessment
Health Problem: Major depressive disorder (MDD), a serious and life-threatening condition, is one of the most common mental disorders in the United States and a leading cause of disability worldwide. MDD is a chronic disease associated with high rates of morbidity and...
by TractManager | Nov 6, 2019 | Emerging Technology Report
Firdapse (amifampridine phosphate) is an oral voltage-gated potassium channel inhibitor for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. Firdapse increases the release of acetylcholine from nerve cells, prolonging the depolarization...
by TractManager | Nov 5, 2019 | Health Technology Assessment
Health Problem: Peritoneal mesothelioma (PM) is a rare primary tumor affecting the serosal (watery) lining of the peritoneum.Technology Description: Hyperthermic intraperitoneal chemotherapy (HIPC) is used as an adjunct to surgery for the treatment of peritoneal...
Recent Comments